Search clinical trials for: imatinib (STI571)

Total 1424 results

Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

PLATFORM Study of Precision Medicine for Rare Tumors

Rare Tumor
Center Trials & Treatment Europe
Center Trials & Treatment

Active, not recruiting

Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma (DPTA)

Non Small Cell Lung Cancer

Georgia
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (PASSION)

Small-cell Lung Cancer

China
Nanchong Central Hospital

Withdrawn

Apatinib for Resectable Colorectal Cancer

Colorectal Cancer | Surgery | Outcome, Fatal | Adjuvant Chemotherapy | Apatinib

China
Boehringer Ingelheim

Completed

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Neoplasms

Belgium
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

Glioma
Novartis

Completed

Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis

Tinea Pedis

China
Peking University Cancer Hospital & Institute

Recruiting

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Digestive System Cancers

China
AIPING ZHOU

Recruiting

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Esophagus Squamous Cell Carcinoma

China
Sun Yat-sen University

Recruiting

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Hepatocellular Carcinoma

China
Qilu Hospital of Shandong University

Recruiting

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Gastric Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Active, not recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Breast Cancer

China
Peking Union Medical College Hospital

Completed

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN (GTN)

Gestational Trophoblastic Disease

China
Biogen

Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
Guangxi Medical University

Unknown

The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute

Unknown

Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

Non Small Cell Lung Cancer

China
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc

Completed

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Leukemia

United States
Instituto Nacional de Cancerologia de Mexico

Completed

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | EGFR | HER-2

Mexico
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors (HS:Hansoh;)

Advanced Cancer

China
Zhejiang Cancer Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University; First... and other collaborators

Unknown

Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study

Hepatocellular Carcinoma | Pulmonary Metastasis
Novartis Pharmaceuticals

Completed

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer (INV342)

Prostate Cancer

Germany
SCRI Development Innovations, LLC
Bayer; Boehringer Ingelheim; Exelixis; Foundation Medicine

Completed

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Non-small Cell Lung Carcinoma | Urothelial Carcinoma | Gastrointestinal Carcinoma, Non-colon | Upper Aerodigestive Tract Carcinoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Advanced Biliary Tract Carcinoma | Advanced Primary Liver Cancer

China
Intergroupe Francophone de Cancerologie Thoracique

Completed

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (ACE-Lung)

Non Small Cell Lung Cancer

France
Peking Union Medical College Hospital

Unknown

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

China
First Affiliated Hospital Bengbu Medical College

Recruiting

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Triple-negative Breast Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Intrahepatic Cholangiocarcinoma

China
Ruijin Hospital

Active, not recruiting

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (PROACH)

Pulmonary Metastases | Osteosarcoma | Apatinib

China
Sun Yat-sen University

Withdrawn

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

ICC

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Leukemia

United States
The Netherlands Cancer Institute
Boehringer Ingelheim; Merck Serono International SA

Completed

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (AFACET)

Carcinoma, Non-Small-Cell Lung

Netherlands
The First People's Hospital of Changzhou

Active, not recruiting

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Stomach Neoplasms
Boehringer Ingelheim

Completed

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Neoplasms

France
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male Volunteers

Healthy
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients (ICOGEN)

Non-small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Breast Cancer | Chemotherapy-induced Nausea and Vomiting

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

PD-L1 Positive Non-small Cell Lung Cancer
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Junling Li

Recruiting

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Advanced Non Squamous NSCLC

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Locally Advanced or Metastatic and Unresectable HCC

United States, Spain, China, Taiwan, Belgium, Korea, Republic of, Italy, Hong Kong, Russian Federation, Ukraine, Turkey, Poland, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Leukemia

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Lung Neoplasms
Fudan University

Not yet recruiting

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Neoplasms | Stomach Neoplasms | Gastrointestinal Neoplasms | Digestive System Neoplasms | Stomach Diseases | Molecular Mechanisms of Pharmacological Action | Capecitabine | Apatinib
Cancer Institute and Hospital, Chinese Academy...

Unknown

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
The First People's Hospital of Changzhou

Active, not recruiting

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Adenocarcinoma of Lung
Boehringer Ingelheim

Completed

BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers

Healthy
University of Utah
Elevar Therapeutics

Terminated

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (APPEASE)

Urothelial Carcinoma | Advanced Malignancies | Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | MSI-H or dMMR Solid Tumors

United States
First Affiliated Hospital of Guangxi Medical University

Unknown

A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma

Biliary Carcinoma

China

3

Subscribe